Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis

Table 4 Linear regression analysis of S100A12 in 138 patients with established rheumatoid arthritis (RA)

Variable	β	SE	t	Pvalue	95% Confidence interval
Univariate analysis:
ACPA	0.75	0.16	4.59	< 0.001	0.43 to 1.08
RF	0.62	0.17	3.66	< 0.001	0.29 to 0.96
Carriage of HLA-DRB1*0401	0.32	0.18	1.79	0.08	-0.03 to 0.66
Carriage of shared epitope	0.32	0.19	1.68	0.10	-0.06 to 0.71
History of diabetes	0.52	0.23	2.23	0.03	0.06 to 0.97
S100A9^a	0.36	0.07	5.46	< 0.001	0.23 to 0.49
S100A8^a	0.19	0.04	4.23	< 0.001	0.10 to 0.28
sRAGE^a	-0.28	0.16	-1.70	0.09	-0.61 to 0.05
Multivariate analysis:
ACPA	0.63	0.15	4.21	< 0.001	0.33 to 0.93
S100A9^a	0.31	0.06	4.87	< 0.001	0.18 to 0.43
History of diabetes	0.43	0.20	2.18	0.03	0.04 to 0.82

Variables that were not listed in the simple linear regression model did not achieve P < 0.1. Adjusted R² of the multiple linear regression model = 0.30.
^aLogarithmic (base e) transformation. S100A12 was logarithmically (base e) transformed.
ACPA, anti-citrullinated peptide antibodies; HLA, human leukocyte antigen; RF, rheumatoid factor; (s)RAGE, (soluble) receptor for advanced glycation end products.

ISSN: 1478-6362